Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Daunorubicin + Fingolimod |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Daunorubicin | Cerubidine | Rubidomycin|daunomycin hydrochloride|rubomycin C|Acetyladriamycin | Chemotherapy - Anthracycline 13 | Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov). |
Fingolimod | Gilenya | FTY720 | PP2A Activator 7 | Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator that activates PP2A, which may result in restoration of tumor suppressor activity thereby leading to apoptosis and inhibition of cell proliferation (PMID: 24448818). Gilenya (fingolimod) is FDA approved for multiple sclerosis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | sensitive | Daunorubicin + Fingolimod | Preclinical - Patient cell culture | Actionable | In a preclinical study, treatment with the combination of Gilenya (fingolimod) and Cerubidine (daunorubicin) resulted in cell death in two acute myeloid leukemia cell lines harboring KMT2A rearrangements, and resulted in decreased colony formation in cells derived from a patient-derived xenograft (PDX) model in culture (PMID: 37891368) | 37891368 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|